Articles

Poll

Podcasts

Slideshows

Videos

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

This month in review spotlights HCPLive’s coverage of gastroenterology pipeline news, a feature about gastroparesis and migraine, and recent GI research.

Gastroenterology Month in Review: January 2025

The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.

FDA Grants Tentative Approval to Generic Version of Rifaximin for IBS-D

This year in review spotlights top GI FDA news from 2024 and new clinical guidance from the American Gastroenterological Association.

Gastroenterology Year in Review: 2024

Post-hoc analysis findings suggest tenapanor improves both abdominal and bowel symptoms in adult patients with IBS-C.

Tenapanor Improves Abdominal Symptoms Independent of Bowel Symptoms in IBS-C

Frissora reviews findings from a cost-effectiveness analysis comparing the Vibrant System to linaclotide for CIC management.

Christine Frissora, MD: Vibrant System’s Role in Chronic Idiopathic Constipation Care

Patients with IBS had different dietary patterns than matched general population controls, with poor diet diversity and quality linked to symptom severity.

Lower Diet Diversity, Quality Linked to More Severe IBS Symptoms

Study findings highlight systemic and local autonomic imbalance in patients with IBS-C, pointing to the value of autonomic modulation in this population.

Autonomic Modulation May Benefit Patients with Constipation-Predominant IBS

This month in review spotlights GI pipeline updates and news from the 2024 NASPGHAN and ACG annual meetings.

Gastroenterology Month in Review: November 2024

Bifidobacterium longum 35624TM reduces IBS symptom severity in children and adolescents, according to a study presented at NASPGHAN 2024.

B. longum 3562 Improves IBS Severity in Children but Does Not Persist after Intake

NASPGHAN 2024 data suggests children and adolescents with a history of COVID-19 were twice as likely to develop IBS during the follow-up period. 

Children Who Contracted COVID-19 Twice as Likely to Develop IBS, Study Finds

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Irritable Bowel Syndrome